Demo
AMPH Nasdaq· Amphastar Pharmaceuticals Inc.
FundamentalsNews digest Peer analysis
Login
AMPH Nasdaq· Amphastar Pharmaceuticals Inc.
Earnings report Q3 2023

AMPHASTAR PHARMACEUTICALS, INC. Reports Strong Revenue Growth in Latest Quarter

Segments of revenue

In the latest quarter, AMPHASTAR PHARMACEUTICALS, INC. reported total net revenues of $180.56 million. The majority of the revenue came from product revenues, which amounted to $151.86 million. Other revenues contributed $28.70 million to the total net revenues.

Strengths

AMPHASTAR PHARMACEUTICALS, INC. demonstrated strong revenue growth in the latest quarter, with a significant increase compared to the same period last year. Product revenues increased by approximately 26%, from $120.13 million to $151.86 million. This growth can be attributed to various factors, such as increased demand for the company's pharmaceutical products and successful product launches. Management comments were not provided in the report.

Challenges

While AMPHASTAR PHARMACEUTICALS, INC. experienced revenue growth, it also faced challenges in managing its operating expenses. The company's operating expenses increased from $35.28 million to $35.73 million in the latest quarter. This increase can impact the company's profitability and overall financial performance.

Noteworthy

AMPHASTAR PHARMACEUTICALS, INC. achieved a significant increase in net income in the latest quarter. Net income rose from $15.87 million to $49.22 million, representing a growth of approximately 210%. This notable increase in net income can be attributed to the strong revenue growth and effective cost management by the company.

Summary

AMPHASTAR PHARMACEUTICALS, INC. delivered a strong performance in the latest quarter, driven by robust revenue growth. The company's product revenues increased by 26%, contributing to a significant rise in net income. However, the company also faced challenges in managing its operating expenses, which increased during the quarter. Overall, AMPHASTAR PHARMACEUTICALS, INC. demonstrated positive financial performance and showed potential for continued growth in the pharmaceutical industry.

Source documents

Form 10-Q  filed on Nov 08, 2023
68 pages scanned

Reference data

Company financials Q3 revenue 178M
Analyst estimates Q3 EPS beat by 27.54%
Sign up to Fey

Get in-depth analysis on thousands of stocks for just $30/month. Cancel anytime.